Brought to you by 
University of Oxford spins off NightstaRx; raises £12mm through its Series A round
15 Dec 2015
Executive Summary
The University of Oxford spun off biotech NightstaRx Ltd. to develop and market retinal dystrophy therapeutics. Concurrent with its formation, Syncona (a subsidiary of the Wellcome Trust) made a £12mm ($19.8mm) investment in NightstarRx's Series A round. Imperial Innovations (the technology transfer arm of Imperial College) also participated.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
University of Oxford spins off NightstaRx; raises £12mm through its Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice